<SEC-DOCUMENT>0001144204-19-001280.txt : 20190110
<SEC-HEADER>0001144204-19-001280.hdr.sgml : 20190110
<ACCEPTANCE-DATETIME>20190110083024
ACCESSION NUMBER:		0001144204-19-001280
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20190107
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190110
DATE AS OF CHANGE:		20190110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ABEONA THERAPEUTICS INC.
		CENTRAL INDEX KEY:			0000318306
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				830221517
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15771
		FILM NUMBER:		19519297

	BUSINESS ADDRESS:	
		STREET 1:		3333 LEE PARKWAY
		STREET 2:		SUITE 600
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75219
		BUSINESS PHONE:		2149055100

	MAIL ADDRESS:	
		STREET 1:		3333 LEE PARKWAY
		STREET 2:		SUITE 600
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75219

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PLASMATECH BIOPHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20140922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ACCESS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19960209

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHEMEX PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tv510807_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, DC 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(D) OF THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of report (Date of earliest event reported):
<B>January 7, 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 14pt"><B><U>ABEONA
THERAPEUTICS INC.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>Delaware</U></B></FONT></TD>
    <TD STYLE="width: 34%; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>001-15771</U></B></FONT></TD>
    <TD STYLE="width: 33%; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>83-0221517</U></B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(State or other jurisdiction of</FONT><BR>
<FONT STYLE="font-size: 10pt">incorporation)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Commission File Number)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(I.R.S. Employer Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>1330 Avenue of the Americas, 33rd Floor,
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>New York, NY 10019 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive offices)
(Zip Code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>(646) 813-4712</U></B><BR>
(Registrant&rsquo;s telephone number, including area code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>N/A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Former name or former address, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see<I>&nbsp;</I>General
Instruction A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Emerging growth company <FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><FONT STYLE="font-size: 10pt"><B>Item 5.02</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Departure of Directors
or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</B></FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 7, 2019,
the Board of Directors (the &ldquo;Board&rdquo;) of Abeona Therapeutics Inc. (the &ldquo;Company&rdquo;) appointed Christine Berni
Silverstein, its Senior Vice President, Finance &amp; Investor Relations, as Chief Financial Officer of the Company effective January
8, 2019 (the &ldquo;Effective Date&rdquo;). In such role, Ms. Silverstein is replacing Stephen B. Thompson, the Company&rsquo;s
previous principal financial officer, who retired effective December 31, 2018, as disclosed in its Current Report on Form 8-K/A filed
on October 5, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Ms. Silverstein, age
36, previously served as the Company&rsquo;s Senior Vice President, Finance &amp; Investor Relations since May 2016. From 2014
through April 2016, Ms. Silverstein served as Head of Investor Relations at Relmada Therapeutics, Inc., a clinical stage specialty
pharmaceutical company. From 2013 to 2014, Ms. Silverstein served as a managing director at SCO Financial Group, a New York-based
corporate advisory firm, where she drove strategy on capital formation and business development opportunities for portfolio companies.
Ms. Silverstein began her career as an investment advisor at Royal Alliance Associates, Inc. in 2003, and from 2006 to 2010 led
teams at corporate advisory firms The Investor Relations Group and Corporate Profile, LLC. A member of the National Investor Relations
Institute, Ms. Silverstein holds a B.S. from the Peter Tobin College of Business, St. John&rsquo;s University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In her new role as
Chief Financial Officer, Ms. Silverstein will receive an annual base salary of $350,000 and will be eligible for an annual discretionary
bonus with a target of 30% of her annual base salary. Subject to approval of the Board&rsquo;s Compensation Committee at its first
regularly scheduled meeting after the Effective Date, Ms. Silverstein will be granted stock options to purchase 20,000 shares of
the Company&rsquo;s common stock pursuant to the Company&rsquo;s 2015 Equity Incentive Plan, with 25% vesting on the one-year anniversary
of the Effective Date and the remaining 75% vesting in 36 equal monthly installments thereafter. Ms. Silverstein will be eligible
to participate in all employee benefit plans that the Company may establish for similarly situated employees, if and to the extent
she is eligible pursuant to the terms of such plans and Company policies, which may be modified by the Company at its discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, on
January 7, 2019, the Board appointed Edward Carr as Chief Accounting Officer effective on the Effective Date. Mr. Carr has been
serving as the Company&rsquo;s Vice President, Controller and principal accounting officer since November 26, 2018. The
Company announced Mr. Carr&rsquo;s appointment as Vice President, Controller in its Current Report on Form 8-K filed on
November 9, 2018. Mr. Carr&rsquo;s compensation has not changed as a result of his appointment as Chief Accounting
Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><FONT STYLE="font-size: 10pt"><B>Item 7.01</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Regulation FD Disclosure.</B></FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 8, 2019,
the Company issued a press release announcing the appointment of Ms. Silverstein and Mr. Carr to serve as the Company&rsquo;s Chief
Financial Officer and Chief Accounting Officer, respectively. A copy of the press release is furnished as Exhibit 99.1 to this
Current Report on Form 8-K and is incorporated into this Item 7.01 by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information included
in Item 7.01 of this Current Report on Form 8-K and the exhibit related hereto shall not be deemed &ldquo;filed&rdquo; for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), or otherwise subject to the
liabilities of that section, and shall not be incorporated by reference into any filing of the Company under the Securities Act
of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><FONT STYLE="font-size: 10pt"><B>Item 9.01</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Financial Statements
and Exhibits.</B></FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>(d) Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 10%; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B><U>Exhibit No.</U></B></FONT></TD>
    <TD STYLE="width: 2%; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: justify; width: 88%"><FONT STYLE="font-size: 10pt"><B><U>Description</U></B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: justify"><A HREF="tv510807_ex10-1.htm"><FONT STYLE="font-size: 10pt">10.1</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: justify"><A HREF="tv510807_ex10-1.htm"><FONT STYLE="font-size: 10pt">Offer Letter, dated January 8, 2019, by and between Abeona Therapeutics Inc. and Christine Berni &nbsp;Silverstein</FONT></A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: justify"><A HREF="tv510807_ex99-1.htm"><FONT STYLE="font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: justify"><A HREF="tv510807_ex99-1.htm"><FONT STYLE="font-size: 10pt">Press Release dated January 8, 2019, entitled &ldquo;Abeona Therapeutics Strengthens Financial Leadership with New Executive Appointments&rdquo;</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt">Abeona Therapeutics Inc.</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt">(Registrant)</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 30%">&nbsp;</TD>
    <TD STYLE="width: 12%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Neena M. Patil</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Neena M. Patil</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">General Counsel and Secretary </FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: January 10, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>tv510807_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.75pt; text-align: right">Exhibit 10.1</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.75pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: right">&nbsp;<IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>January 8, 2019&#9;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.75pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">C/O Christine Berni Silverstein</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.75pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.75pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Christine:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">I am
pleased to offer you the position of Senior Vice President, Chief Financial Officer with Abeona Therapeutics Inc. (the &ldquo;<U>Company</U>&rdquo;)
reporting to the CEO, effective January 8, 2019, (the &ldquo;<U>Effective Date</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 6.75pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Your
position will be exempt, and you will be based in our New York office.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><U>1.&nbsp;&nbsp;Compensation
and benefits</U>.</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.75pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Your annualized base salary of $350,000
(subject to required tax withholdings and other authorized deductions) will be paid at a semi-monthly rate of $14,583.33 in accordance
with customary payroll practices and procedures, subject to applicable law. This salary covers all hours worked by exempt employees.
You will receive your semi-monthly pay on the 15<SUP>th</SUP> and the last day of each month.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During your employment,
you may be considered for an annual discretionary bonus (&ldquo;<U>Annual Bonus</U>&rdquo;) in addition to your Base Salary with
a target of 30% of your Base Salary (&ldquo;<U>Target Annual Bonus Opportunity</U>&rdquo;). Annual Bonus compensation in any year,
if any, will be determined in the Company sole discretion and shall be based on your performance and that of the Company, as well
as market factors, in accordance with a general bonus program established by the Compensation Committee (the &ldquo;<U>Compensation
Committee</U>&rdquo;) of the Board of Directors of the Company (the &ldquo;<U>Board</U>&rdquo;). Except as provided below in the
event of certain terminations of your employment, to be eligible to receive an Annual Bonus for any year, if any, you must be employed
in good standing on the date that the Annual Bonus is paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">You will be eligible
to participate in employee benefit plans that the Employer may establish for similarly situated employees, except to the extent
such plans are duplicative of benefits otherwise provided under any other agreement. Your participation will be subject to the
terms of the applicable plan documents and generally applicable Company policies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">These plans are subject
to review and change at any point, however, currently we offer comprehensive health, vision and dental insurance, employer funded
life, short- and long-term disability insurance and up to 4% employer matching on 401k contributions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><U>2.&nbsp;&nbsp;Stock
Options</U>.</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Subject
to Compensation Committee approval, at the first regularly scheduled meeting of the Compensation Committee after the Effective
Date, you will be granted</FONT> stock options (&ldquo;<U>Options</U>&rdquo;) <FONT STYLE="font-size: 10pt">under the Abeona Therapeutics
Inc. 2015 Equity Incentive Plan (the &ldquo;<U>Plan</U>&rdquo;) to purchase 20,000 shares of Company common stock. The Option Shares
will vest over a forty-eight (48) month period, with one quarter (25%) vesting on the one-year anniversary of the Effective Date
and the remaining seventy-five percent (75%) of the Options vesting in equal monthly installments thereafter over the remaining
thirty-six (36) months, commencing with the first month following the first anniversary of the Effective Date, and subject to (i)
your continued employment with the Company and/or its affiliates through to the applicable vesting dates, and (ii) the terms and
conditions of the Plan and the agreement memorializing the terms of the Options. If you remain continuously employed from the Effective
Date through the date of a Change in Control (as defined below), any unvested portion of the Options as of the date of the Change
in Control shall become fully vested immediately prior to the date of the Change in Control. Pursuant to the terms of the Plan,
the exercise price of the Options will be the fair market value of the Company&rsquo;s common stock on the date of the grant. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><U>3.&nbsp;&nbsp;Employment Termination</U>.</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company may terminate
your employment for any reason, and you may voluntarily terminate your employment hereunder for any reason, in each case at any
time upon written notice to the other party (the date on which your employment terminates for any reason is herein referred to
as the &ldquo;<U>Termination Date</U>&rdquo;). Upon your termination of employment for any reason, you (or your beneficiary or
estate, as applicable, in the event of your death) will be entitled to (i) payment of any Base Salary earned but unpaid through
the Termination Date, (ii) any accrued unused vacation days, (iii) additional vested benefits (if any) in accordance with the applicable
terms of applicable Company arrangements, and (iv) any unreimbursed expenses in accordance with the Company&rsquo;s business expense
reimbursement policies (collectively, the &ldquo;<U>Accrued Amounts</U>&rdquo;); <U>provided</U>, <U>however</U>, that if your
employment hereunder is terminated (a) by the Company without Cause (as defined below), (b) by you for Good Reason (as defined
below), (c) on account of your death or (d) by the Company on account of your Disability (as defined below), then you will be eligible
to receive any Annual Bonus awarded in a prior year, but not yet paid or due to be paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If your employment
is terminated (a) by the Company other than for Cause, death or Disability or (b) by you for Good Reason, in addition to the Accrued
Amounts, you will be entitled to: (i) a payment equal to the sum of your Base Salary plus your Target Annual Bonus Opportunity
(such amount, the &ldquo;<U>Severance Amount</U>&rdquo;); (ii) a payment equal to the premiums that you would pay if you elected
continued health coverage under the Company&rsquo;s health plan for you and your eligible dependents for the twelve (12) month
period following the Termination Date, less the applicable active employee rate, which premiums will be calculated based on the
rate determined under the COBRA rate in effect on the Termination Date (&ldquo;<U>Medical Benefit Payment</U>&rdquo;); (iii) a
pro-rata Annual Bonus, which pro-rated Annual Bonus shall be determined by multiplying the full year Annual Bonus that would otherwise
have been awarded to you, based upon the achievement of the applicable performance goals for the year in which the Termination
Date occurs (without any exercise of negative discretion disproportionate to any such exercise respecting other executives and
all subjective performance requirements deemed fully satisfied), multiplied by a fraction, the numerator of which is the number
of days during which you were employed by the Company in the year in which the Termination Date occurs and the denominator of which
is three hundred sixty-five (365); and (iv) accelerated vesting equivalent to twelve (12) months of continued employment from the
Termination Date (disregarding such termination for such purpose) with respect to all unvested equity and any other long-term incentive
awards granted to you and then outstanding on the Termination Date; <U>provided</U>, <U>that</U>, any delays in the settlement
or payment of such awards that are set forth in the applicable award agreement and that are required under Section 409A of the
Internal Revenue Code, as amended (the &ldquo;<U>Code</U>&rdquo;), and the Treasury Regulations thereunder (&ldquo;<U>Section 409A</U>&rdquo;)
shall remain in effect. The Company&rsquo;s obligations to make the payments and provide the benefits set forth in (i) &ndash;
(iv) in this Paragraph shall be conditioned upon your continued compliance with your obligations under Section 4 below and your
execution and nonrevocation of a release of claims in favor of the Company and its affiliates in a form provided by the Company
(&ldquo;<U>Release</U>&rdquo;). Notwithstanding any provision to the contrary herein, and without limitation of any remedies to
which the Company may be entitled, (A) the Severance Amount shall be paid in installments in accordance with the Company&rsquo;s
regular payroll practices during a twelve (12) month period commencing within sixty (60) days following the Termination Date (with
the first such payment to include all installment amounts from the Termination Date), (B) the Medical Benefit Payment will be made
in a lump sum within sixty (60) days following the Termination Date and (C) the pro-rated Annual Bonus shall be paid to you in
the ordinary course at the same time annual bonuses are paid to other senior executives, but in no event later than March 15 of
the year following the year in which the Termination Date occurs; <U>provided</U>, <U>that</U>, the Release is effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Notwithstanding any
other provision contained herein, if your employment hereunder is terminated by you for Good Reason or by the Company without Cause
(other than on account of your death or Disability), in each case within twelve (12) months following a Change in Control, you
will be entitled to receive the Severance Amount, the Medical Benefit Payment, and the pro-rata Annual Bonus, as provided above,
except that (i) if the Change in Control is a &ldquo;change in control event&rdquo; as defined under Section 409A, the Severance
Amount shall be payable in a lump sum within sixty (60) days following the Termination Date; and (ii)&nbsp;notwithstanding the
terms of any equity incentive plan or award agreements, as applicable, all outstanding unvested stock options/stock appreciation
rights granted to your during your employment with the Company shall become fully vested and exercisable and will remain exercisable
for six (6) months following the Termination Date and all outstanding equity-based and other long-term compensation awards, other
than stock options/stock appreciation rights, shall become fully vested and the restrictions thereon shall lapse; <U>provided</U>,
<U>that</U>, any delays in the settlement or payment of such awards that are set forth in the applicable award agreement and that
are required under Section 409A shall remain in effect. The Company&rsquo;s obligations to provide the payments and benefits described
in this Paragraph shall be conditioned upon your continued compliance with your obligations under Section 4 below and your execution
and delivery to the Company of an effective Release.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The foregoing payments
and benefits upon termination of your employment shall constitute the exclusive severance payments and benefits due to you upon
a termination of your employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Upon your termination
of employment with the Company for any reason, you will be deemed to have resigned, as of the Termination Date, from all positions
you then hold with the Company and its affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Following the termination
of your employment with the Company for any reason, you will reasonably cooperate with the Company upon reasonable request of the
CEO or the Board or and be reasonably available to the Company (taking into account your other business endeavors) with respect
to matters arising out of your services to the Company and its subsidiaries, including, in connection with any legal proceeding,
providing testimony and affidavits; <U>provided</U>, <U>that</U>, the Company shall make reasonable efforts to minimize disruption
of your other activities. The Company shall reimburse you for reasonable expenses <FONT STYLE="color: #191919">including reasonably
incurred attorney&rsquo;s fees </FONT>incurred in connection with such cooperation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">For purposes of this
offer letter, the following terms have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Cause</U>&rdquo;
shall mean: (a) your substantial failure to perform your duties (other than any such failure resulting from incapacity due to physical
or mental disability) that continues for fifteen (15) calendar days after written notice from the Company; (b) your failure to
comply with any valid and legal directive of the CEO or the Board (as applicable) that continues for fifteen (15) calendar days
after written notice from the Company; (c) your engagement in dishonesty, illegal conduct, or misconduct (or the discovery of your
having engaged in such conduct), which, in each case, materially harms or is reasonably likely to materially harm the Company or
its subsidiaries; (d) your embezzlement, misappropriation, or fraud, whether or not related to your employment with the Company;
(e) your conviction of or plea of guilty or nolo contendere to a crime that constitutes a felony; (f) your willful violation of
a material policy of the Company; (g) your willful or grossly negligent unauthorized disclosure of Confidential Information (as
defined below); or (h) your material breach of any material obligation under this offer letter or any other written agreement between
you and the Company that continues for fifteen (15) calendar days after written notice from the Company (if such breach is reasonably
curable); or (i) any willful material failure by you to comply with the Company&rsquo;s written policies or written rules, as they
may be in effect from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Change
in Control</U>&rdquo; shall have the meaning defined in subparagraph (ii) of the definition of such term under the Appendix in
the Plan as in effect on the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Disability</U>&rdquo;
shall occur, subject to applicable law, when you are entitled to receive long-term disability benefits under the Company&rsquo;s
long-term disability plan, or if there is no such plan, your inability, due to physical or mental incapacity, to perform the essential
functions of your job for one hundred eighty (180) calendar days out of any three hundred sixty-five (365) day period or one hundred
twenty (120) consecutive calendar days. Any question as to the existence of your Disability as to which you and the Company cannot
agree shall be determined in writing by a qualified independent physician mutually acceptable to you and the Company. If you and
the Company cannot agree as to a qualified independent physician, each shall appoint such a physician and those two physicians
shall select a third who shall make such determination in writing. The determination of Disability made in writing to the Company
and you shall be final and conclusive for all purposes of this offer letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<U>Good
Reason</U>&rdquo; shall mean the occurrence of any of the following, in each case without your written consent: (a) a material
reduction of at least ten percent (10%) of your Base Salary other than a general reduction in Base Salary that affects all similarly
situated executives in substantially the same position; (b) a material reduction of at least thirty percent (30%) of the Target
Annual Bonus Opportunity other than a general reduction in the Target Annual Bonus Opportunity that affects all similarly situated
executives in substantially the same position; (c) a permanent relocation of your principal place of employment by more than thirty-five
(35) miles; (d) any material breach by the Company of any material provision of this offer letter; or (e) a material adverse change
in your title, authority, duties, or responsibilities (including the reporting structure applicable to you, other than temporarily
while you are physically or mentally incapacitated); <U>provided</U>, <U>however</U>, that you cannot terminate your employment
for Good Reason unless you have provided written notice to the Company of the existence of the circumstances providing grounds
for termination for Good Reason within sixty (60) calendar days following the initial existence of such grounds and the Company
has had thirty (30) calendar days from the date on which such notice is provided to cure such circumstances. If you do not terminate
your employment for Good Reason within sixty (60) calendar days after expiration of the cure period (in which the Company shall
not have so cured such grounds), then you will be deemed to have waived your right to terminate for Good Reason with respect to
such grounds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><U>4.&nbsp;&nbsp;Restrictive Covenants</U>.</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This offer
of employment is contingent on your signing the Company&rsquo;s standard Employee Confidentiality, Non-competition, Policy on Insider
Trading, Whistle Blower Policy, Code of Ethics, Proprietary Information Agreement, attached hereto as <U>Exhibit A</U>, the terms
of which are incorporated by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.35pt 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><U>5.&nbsp;&nbsp;At-Will Employment</U>.</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.35pt 0pt 6.75pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Your employment
with the Company is at-will. This means that you will have the right to terminate your employment relationship with the Company
at any time for any reason. Similarly, the Company will have the right to terminate its employment relationship with you at any
time for any reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B><U>6.&nbsp;&nbsp;Miscellaneous</U>.</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">All amounts
paid to you under this offer letter during or following your employment shall be subject to withholding and other employment taxes
imposed by applicable law, and the Company shall withhold from any payments under this offer letter all federal, state and local
taxes as the Company is required to withhold pursuant to any law or governmental rule or regulation. You shall be solely responsible
for the payment of all taxes imposed on you relating to the payment or provision of any amounts or benefits hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 6.75pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This offer
letter may be executed by .pdf or facsimile signatures in any number of counterparts, each of which shall be deemed an original,
but all such counterparts shall together constitute one and the same instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 6.75pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">From and
after the Effective Date, this offer letter (including <U>Exhibit A</U> hereto) constitutes the entire agreement between you and
the Company, and supersedes all prior representations, agreements and understandings (including any prior course of dealings),
both written and oral, between you and the Company with respect to the subject matter hereof. In the event of any inconsistency
between this offer letter and any other plan, program, practice or agreement in which you are a participant or a party, this offer
letter shall control unless such other plan, program, practice or agreement is more favorable to you (term by term) or specifically
refers to this offer letter as not controlling.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This offer
letter and any of the provisions hereof may be amended, waived (either generally or in a particular instance and either retroactively
or prospectively), modified or supplemented, in whole or in part, only by written agreement signed by you and the Company. This
offer letter and your rights and obligations hereunder, may not be assigned by you, and any purported assignment by you in violation
hereof shall be null and void. The Company is authorized to assign this offer letter to a successor to substantially all of its
assets or business. Nothing in this offer letter shall confer upon any person not a party hereof, or the legal representatives
of such person, any rights or remedies of any nature or kind whatsoever under or by reason of this offer letter, except the personal
representative of the deceased. This offer letter shall inure to the benefit of, and be binding on, the successors and assigns
of each of the parties, including, without limitation, your heirs and the personal representatives of your estate and any successor
to all or substantially all of the business and/or assets of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 6.75pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">No remedy
conferred upon a party by this offer letter is intended to be exclusive of any other remedy, and each and every such remedy shall
be cumulative and shall be in addition to any other remedy given under this offer letter or now or hereafter existing at law or
in equity. Except as explicitly provided herein, no delay or omission by a party in exercising any right, remedy or power under
this offer letter or existing at law or in equity shall be construed as a waiver thereof, and any such right, remedy or power may
be exercised by such party from time to time and as often as may be deemed expedient or necessary by such party in its sole discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This offer
letter shall be construed and enforced in accordance with, and the laws of the State of New York, without giving effect to the
conflicts of law principles thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Any reference
to a Section of the Code shall be deemed to include any successor to such Section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 6.75pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This offer letter and the compensation payable
hereunder shall be subject to any applicable clawback or recoupment policies, share trading policies, and other policies that may
be implemented by the Board from time to time with respect to officers of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Any notices required or permitted hereunder
or necessary or convenient in connection herewith shall be in writing and shall be deemed to have been given when hand delivered
or mailed by registered or certified mail, if to the Company, to the CEO at the address above, and if to you at the most recent
address in the Company&rsquo;s records.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Please acknowledge
your acceptance of this offer by returning a signed copy of this offer letter. If there are any other agreements of any type that
you are aware of that may impact or limit your ability to perform your job at the Company, please let us know as soon as possible.
In accepting this offer, you represent and warrant to the Company that you are not subject to any legal or contractual restrictions
that would in any way impair your ability to perform your duties and responsibilities to the Company, and that all information
you provided to the Company is accurate and complete in all respects. This offer will remain open until January 8, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Formalities
aside, we are very excited about having you join our team. Your skills and experiences are a great match with our goals, and I
anticipate you being a critical part of the Company&rsquo;s success.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9.55pt 0pt 6.75pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Very truly yours,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Joao Siffert</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Interim CEO and Chief Medical officer</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Abeona Therapeutics Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">I accept this offer of
employment with Abeona Therapeutics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%; padding-right: 5.4pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature:</FONT></TD>
    <TD STYLE="width: 10%; padding-right: 5.4pt; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="width: 25%; padding-right: 5.4pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="width: 40%; padding-right: 5.4pt; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; text-align: justify; text-indent: 0in; border-bottom: Black 1pt solid"></TD>
    <TD STYLE="padding-right: 5.4pt; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; text-align: justify; text-indent: 0in; border-bottom: Black 1pt solid"></TD>
    <TD STYLE="padding-right: 5.4pt; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.75pt; text-align: justify; text-indent: 0in"></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.75pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>EMPLOYEE CONFIDENTIALITY, NON-COMPETITION,
AND PROPRIETARY INFORMATION AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.75pt; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">AGREEMENT, effective as of <B>January
8, 2019</B> between Abeona Therapeutics Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), and <B>Christine Berni
Silverstein</B> (the &ldquo;<U>Employee</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.75pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Employee
will make full and prompt disclosure to the Company of all inventions, improvements, modifications, discoveries, methods, technologies,
biological materials, and developments, and all other materials, items, techniques, and ideas related directly or indirectly to
the business of the Company (collectively, &ldquo;Intellectual Property&rdquo;), whether patentable or not, made or conceived by
Employee or under Employee&rsquo;s direction during Employee&rsquo;s employment with the Company, whether or not made or conceived
during normal working hours, or on the premises of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.75pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Employee
agrees that all Intellectual Property, as defined above, shall be the sole property of the Company and its assigns, and the Company
and its assigns shall be the sole owner of all patents and other rights in connection therewith. Employee hereby assigns to the
Company any rights Employee may have or acquire in all Intellectual Property and all related patents, copyrights, trademarks, trade
names, and other industrial and intellectual property rights and applications therefore, in the United States and elsewhere. Employee
further agrees that with regard to all future developments of Intellectual Property, Employee will assist the Company in every
way that may be reasonably required by the Company (and at the Company&rsquo;s expense) to obtain and, from time to time, enforce
patents on Intellectual Property in any and all countries that the Company may require, and to that end, Employee will execute
all documents for use in applying for and obtaining such patents thereon and enforcing the same, as the Company may desire, together
with any assignment thereof to the Company or persons designated by the Company, and Employee hereby appoints the Company as Employee&rsquo;s
attorney to execute and deliver any such documents or assignments requested by the Company. Employee&rsquo;s obligation to assist
the Company in obtaining and enforcing patents for Intellectual Property in any and all countries shall continue beyond the termination
of Employee&rsquo;s employment with the Company, but the Company shall compensate Employee at a reasonable, standard hourly rate
following such termination for time directly spent by Employee at the Company&rsquo;s request for such assistance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.3pt 0pt 5.75pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Employee
hereby represents that Employee has no continuing obligation to assign to any former employer or any other person, corporation,
institution, or firm any Intellectual Property as described above. Employee represents that Employee&rsquo;s performance of all
the terms of this Agreement and as an employee of the Company does not and will not breach any agreement to keep in confidence
proprietary information acquired by Employee, in confidence or in trust, prior to Employee&rsquo;s employment by the Company. Employee
has not entered into, and Employee agrees not to enter into, any agreement (either written or oral), which would put Employee in
conflict with this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Employee
agrees to assign to the Company any and all copyrights and reproduction rights to any material prepared by Employee in connection
with this Agreement and/or developed during the term of Employee&rsquo;s employment with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Employee
understands and agrees that a condition of Employee&rsquo;s employment and continued employment with the Company is that Employee
has not brought and will not bring to the Company or use in the performance of Employee&rsquo;s duties at the Company any materials
or documents rightfully belonging to a former employer which are not generally available to the public. Employee may bring such
materials and documents to the Company only to the extent that Employee has obtained written authorization from such former employer
for their possession and use. Accordingly, this is to advise the Company that any materials and/or documents belonging to a former
employer and which are not generally available to the public that Employee has brought or will bring to the Company or has used
or will use in Employee&rsquo;s employment are identified in <U>Exhibit A</U> appended to this Agreement, and as to each such item,
Employee represents that Employee has obtained prior to the effective date of this Agreement written authorization for their possession
and use in Employee&rsquo;s employment with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.3pt 0pt 5.75pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.3pt 0pt 5.75pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.3pt 0pt 5.75pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Employee
recognizes that the services to be performed by Employee hereunder are special, unique, and extraordinary and that, by reason of
Employee&rsquo;s employment with the Company, Employee may acquire Confidential Information (as hereinafter defined) concerning
the operation of the Company, the use or disclosure of which would cause the Company substantial loss and damage which could not
be readily calculated and for which no remedy at law would be adequate. Accordingly, Employee agrees that Employee will not (directly
or indirectly) at any time, whether during or after Employee&rsquo;s employment with the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.35pt 0pt 5.75pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify; padding-right: 5.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">knowingly
use for personal benefit or for any other reason not authorized by the Company any Confidential Information that Employee may acquire
or has acquired by reason of Employee&rsquo;s employment with the Company, or;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify; padding-right: 5.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disclose
any such Confidential Information to any person or entity except (A) in the performance of Employee obligations to the Company
hereunder, (B) as required by a court of competent jurisdiction, (C) in connection with the enforcement of Employee rights under
this Agreement, or (D) with the prior consent of the Board of Directors of the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.15pt 0pt 5.75pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As
used herein, &ldquo;<U>Confidential Information</U>&rdquo; includes information with respect to the facilities and methods of the
Company, reagents, chemical compounds, cell lines or subcellular constituents, organisms, or other biological materials, trade
secrets, and other Intellectual Property, systems, patents and patent applications, procedures, manuals, confidential reports,
financial information, business plans, prospects, or opportunities, personnel information, or lists of customers and suppliers;
provided, however, that Confidential Information shall not include any information that is known or becomes generally known or
available publicly other than as a result of disclosure by Employee which is not permitted as described in clause (ii) above, or
the Company discloses same to others without obtaining an agreement of confidentiality.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.15pt 0pt 5.75pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Employee
confirms that all Confidential Information is the exclusive property of the Company. All business records, papers, documents and
electronic materials kept or made by Employee relating to the business of the Company which comprise Confidential Information shall
be and remain the property of the Company during the Employee&rsquo;s employment and at all times thereafter. Upon the termination,
for any reason, of Employee&rsquo;s employment with the Company, or upon the request of the Company at any time, Employee shall
deliver to the Company, and shall retain no copies of any written or electronic materials, records and documents made by Employee
or coming into Employee&rsquo;s possession concerning the business or affairs of the Company and which comprise Confidential Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.3pt 0pt 5.75pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
the term of Employee&rsquo;s employment with the Company and for one (1) year thereafter (the &ldquo;Restricted Period&rdquo;),
the Employee shall not directly or indirectly, for Employee&rsquo;s own account or for the account of others, as an officer, director,
stockholder (other than as the holder of less than 1% of the outstanding stock of any publicly traded company), owner, partner,
employee, promoter, consultant, manager or otherwise participate in the promotion, financing, ownership, operation, or management
of, or assist in or carry on through proprietorship, a corporation, partnership, or other form of business entity which is in competition
with the Company in the field of RNA interference (RNAi) (the &ldquo;Company Business&rdquo;) within the United States or any other
country in which the Company is conducting or is actively seeking or planning to conduct the Company Business as of the date of
such termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.25pt 0pt 5.75pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During
the Restricted Period, the Employee shall not, whether for Employee&rsquo;s own account or for the account of any other person
(excluding the Company): solicit or contact in an effort to do business with any person who was or is a customer of the Company
during the term of this Agreement or after its termination, or any affiliate of any such person, if such solicitation or contact
is for the purpose of competition with the Company; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify; padding-right: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">solicit
or contact in an effort to do business with any person who was or is a customer of the Company during the term of this Agreement
or after its termination, or any affiliate of any such person, if such solicitation or contact is for the purpose of competition
with the Company; or</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify; padding-right: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">solicit
or induce any of the Company&rsquo;s employees to leave their employment with the Company or accept employment with anyone else,
or hire any such employees or persons who were employed by the Company during the preceding 12 months.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Nothing
herein shall prohibit or preclude the Employee from performing any other types of services that are not precluded by this Section
7 for any other person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Employee
has carefully read and considered the provisions of this Section 7 (including the Restricted Period, scope of activity to be restrained,
and the restriction&rsquo;s geographical scope) and concluded them to be fair, appropriate and reasonably required for the protection
of the legitimate business interests of the Company, its officers, directors, employees, creditors, and shareholders. Employee
understands that the restrictions contained in this Section may limit Employee&rsquo;s ability to engage in a business similar
to the Company&rsquo;s business, but acknowledges that Employee will receive adequate and affluent remuneration and other benefits
from the Company hereunder to justify such restrictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The
Employee shall give prompt notice to the Company of the Employee&rsquo;s acceptance of employment or other fees for services relationship
during the Restricted Period, which notice shall include the name of, the business of, and the position that Employee shall hold
with such other employer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event that Employee&rsquo;s employment is transferred by the Company to a subsidiary, affiliated company, or acquiring company
(as the case may be), Employee&rsquo;s employment by such company will, for the purpose of this Agreement, be considered as continued
employment with the Company, unless Employee executes an agreement, substantially similar in substance to this Agreement, and until
the effective date of said agreement in any such company for which Employee becomes employed. It is likewise agreed that no changes
in Employee&rsquo;s position or title will operate to terminate the provisions of this Agreement unless expressly agreed to in
writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
termination of Employee&rsquo;s employment for any reason, unless such employment is transferred to a subsidiary, affiliated or
acquiring company of the Company, Employee agrees to leave with, or return to, the Company all records, drawings, notebooks, and
other documents pertaining to the Company&rsquo;s Confidential Information, whether prepared by Employee or others, as well as
any equipment, tools or other devices owned by the Company, that are then in Employee&rsquo;s possession, however such items were
obtained, and Employee agrees not to reproduce or otherwise retain any document or data relating thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Employee
obligations under this Agreement shall survive the termination of Employee&rsquo;s employment with the Company regardless of the
manner of, and reason for, such termination, and shall be binding upon Employee&rsquo;s heirs, executors, and administrators.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior
to entering the employ of the Company, Employee has lawfully terminated employment with all previous employers. Employee acknowledges
that this Agreement does not constitute a contract of employment for a term and does not otherwise imply that the Company will
continue his or her employment for any period of time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
a matter of record, Employee has identified in Exhibit B, appended to this Agreement, all Intellectual Property relevant to the
subject matter of Employee&rsquo;s employment with the Company, which has been made or conceived or first reduced to practice by
Employee alone or jointly with others prior to Employee&rsquo;s employment with the Company, which Employee desires to exclude
from Employee&rsquo;s obligations under this Agreement; and Employee represents that such list is complete. If there is no such
list set forth in Exhibit B, Employee represents that Employee has no such Intellectual Property at the time of execution of this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
delay or omission by the Company in exercising any right under this Agreement will operate as a waiver of that or any other right.
A waiver or consent given by the Company on any one occasion is effective only in that instance and will not be construed as a
bar to or waiver of any right on any other occasion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Employee
agrees that in addition to any other rights and remedies available to the Company for any breach or threatened breach by Employee
of Employee&rsquo;s obligations hereunder, the Company shall be entitled to enforcement of Employee&rsquo;s obligations hereunder
by whatever means are at the Company&rsquo;s disposal, including court injunction. In the event of any such breach or threatened
breach by Employee, the Company shall be entitled to recover all of its reasonably incurred costs and attorney&rsquo;s fees in
enforcing its rights hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company may assign this Agreement to any other corporation or entity which acquires (whether by purchase, merger, consolidation
or otherwise) all or substantially all of the business and/or assets of the Company. Employee shall have no rights of assignment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
any provision of this Agreement shall be declared invalid, illegal, or unenforceable, then such provision shall be enforceable
to the extent that a court deems it reasonable to enforce such provision. If such provision shall be unreasonable to enforce to
any extent, such provision shall be severed and all remaining provisions shall continue in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> 17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Employee hereby acknowledges receipt of the Company&rsquo;s Confidentiality Policy.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Agreement shall be effective as of the date set forth below next to Employee&rsquo;s signature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">19.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Agreement and the employment offer letter constitute the entire contract between the parties hereto with regard to the subject
matter hereof. They supersede any other agreements, representations or understandings (whether oral or written and whether express
or implied) which relate to the subject matter hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">20.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Agreement shall be governed in all respects by the laws of the State of Delaware. Each of the Company and Employee (a) hereby irrevocably
submits to the exclusive jurisdiction of the state courts of the State of Delaware or the United States District Court located
in the State of Delaware for the purpose of any action between the Company and Employee arising in whole or in part under or in
connection with this Agreement, (b) hereby waives, to the extent not prohibited by applicable law, and agrees not to assert, by
way of motion, as a defense or otherwise, in any such action, any claim that it is not subject personally to the jurisdiction of
the above-named courts, that its property is exempt or immune from attachment or execution, that any such action brought in one
of the above-named courts should be dismissed on grounds of <I>forum non conveniens</I>, should be transferred or removed to any
court other than one of the above-named courts, or should be stayed by reason of the pendency of some other proceeding in any other
court other than one of the above-named courts, or that this Agreement or the subject matter hereof may not be enforced in or by
such court, and (c) hereby agrees not to commence any such action other than before one of the above-named courts. Notwithstanding
the previous sentence, the Company or Employee may commence any action in a court other than the above-named courts solely for
the purpose of enforcing an order or judgment issued by one of the above-named courts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>IN
WITNESS WHEREOF</B>, Employee has executed this Agreement under seal as of the date set forth above:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 293.75pt; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">ACCEPTED AND AGREED TO BY THE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">COMPANY: </FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">EMPLOYEE:</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0; width: 3%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 25%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 10%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 3%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 25%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 34%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; border-bottom: Black 1pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; border-bottom: Black 1pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name: Joao Siffert</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name: </FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title: CEO</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 9; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>tv510807_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><IMG SRC="image_002.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Abeona Therapeutics Strengthens Financial
Leadership<BR>
 with New Executive Appointments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Internal appointments of Christine Silverstein
as Chief Financial Officer and Edward Carr as Chief <BR>
Accounting Officer bolster financial strategy and controls</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NEW&#9;YORK&#9;and&#9;CLEVELAND, Jan. 8,
2019 &ndash; Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company focused on developing
novel cell and gene therapies for life-threatening rare genetic diseases, today announced that it has appointed Christine Silverstein
to the position of Chief Financial Officer and named Edward Carr as Chief Accounting Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;Christine is a thoughtful and strategic
leader who is truly passionate about our Company's commitment to serve patients and shareholders alike. Her healthcare and in-depth
capital markets experience has been instrumental in the implementation of Abeona&rsquo;s financial and operational strategy and
will play a vital role in our ability to generate higher growth and enhance shareholder value,&rdquo; commented Jo&atilde;o Siffert,
M.D., Interim Chief Executive Officer of Abeona. &ldquo;Ed has considerable financial and accounting experience and, in the short
period since joining Abeona, has implemented important financial practices that yielded efficiencies and further strengthened our
operations. Together, Christine and Ed&rsquo;s appointments round out our internal capabilities that are imperative to our success.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ms. Silverstein was previously Senior Vice President, Finance
and Investor Relations for Abeona. Prior to joining Abeona in 2016, she served as Head of Investor Relations at Relmada Therapeutics,
Inc. a clinical stage specialty pharmaceutical company. This was preceded by her role as Managing Director at SCO Financial Group,
where she drove strategy on capital formation and business development opportunities for portfolio companies. Ms. Silverstein began
her career as an investment advisor at Royal Alliance Associates, Inc. before leading teams at corporate advisory firms, The Investor
Relations Group and Corporate Profile, LLC. She is a member of the National Investor Relations Institute and holds a B.S. from
the Peter Tobin College of Business, St. John's University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Prior to Abeona, Mr. Carr most recently served as Vice President
and Assistant Controller at Coty Inc., a publicly listed multinational company. Prior to Coty, he served for more than 10 years
as Chief Accounting Officer at Foster Wheeler AG, which was preceded by his tenure at Ernst &amp; Young LLP. He is a Certified
Public Accountant and holds a B.S. and Master of Professional Accountancy from West Virginia University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><IMG SRC="image_002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Abeona Therapeutics </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Abeona Therapeutics Inc. is a clinical-stage
biopharmaceutical company developing cell and gene therapies for life-threatening rare genetic diseases. Abeona's lead programs
include EB-101, its gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa, and ABO-102, a novel AAV9 based
gene therapy for Sanfilippo syndrome type A (MPS IIIA). The Company&rsquo;s portfolio of AAV9 based gene therapies also features
ABO-101 for Sanfilippo syndrome type B (MPS IIIB), and ABO-201 and ABO-202 for CLN3 disease and CLN1 disease, respectively. Its
preclinical assets include ABO-401, which uses a novel AIM&trade; AAV vector platform to address all mutations of cystic fibrosis.
Abeona has received numerous regulatory designations from the FDA and EMA for its pipeline candidates and is the only company
with Regenerative Medicine Advanced Therapy designation for two investigational therapies (EB-101 and ABO-102). For more information,
visit <U>www.abeonatherapeutics.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward Looking Statements: </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>This press release contains certain statements that are forward-looking
within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended, and that involve risks and uncertainties.&nbsp; These statements include statements about the ability of its
management team to lead the Company and deliver on key strategies, the market opportunities for the Company&rsquo;s products and
product candidates, and the&nbsp;Company&rsquo;s goals and objectives.&nbsp; We have attempted to identify forward looking statements
by such terminology as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo;
&ldquo;expect,&rdquo; &ldquo;intend,&rdquo; and similar expressions (as well as other words or expressions referencing future events,
conditions or circumstances), which constitute and are intended to identify forward-looking statements.&nbsp;Actual results may
differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks
and uncertainties, including but not limited to continued interest in our rare disease portfolio, our ability to enroll patients
in clinical trials, the impact of competition, the ability to secure licenses for any technology that may be necessary to commercialize
our products, the ability to achieve or obtain necessary regulatory approvals, the impact of changes in the financial markets and
global economic conditions, risks associated with data analysis and reporting, and other risks as may be detailed from time to
time in the Company&rsquo;s Annual Reports on Form 10-K and quarterly reports on Form 10-Q and other reports filed by the Company
with the Securities and Exchange Commission.&nbsp; The Company undertakes no obligation to revise the forward-looking statements
or to update them to reflect events or circumstances occurring after the date of this presentation, whether as a result of new
information, future developments or otherwise, except as required by the federal securities laws.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investor Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sofia Warner</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Director, Investor Relations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Abeona Therapeutics Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">+1 (646) 813-4710</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>swarner@abeonatherapeutics.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Media Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Scott Santiamo</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Director, Corporate Communications</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Abeona Therapeutics Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">+1 (718) 344-5843</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>ssantiamo@abeonatherapeutics.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  _ .H# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^H9Y/)C,
MC/&D:\NS],?7M4U<GJEX;7Q/;2:HCK8KG[/LS(-_]XA4R.O<U48<[L95:B@D
MV;AO;I(1+]@DE7;G$1 8G/3:V./?-$.LV4UTUMYICN$&6CD4KCVR>"?H:L07
MMI=*6M[F&50=I,<@89]..]8OC"UMKK1SYD:-=@@6V5#-OR.%!!_E64N:.J)F
MYPBY1=_Z[G19HJAHT=W%I%LM](9+D)\[,><_D/Y5>+*,Y8<=>>E4M4;1=TF+
M129!Q@CGI2TQA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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B.*<T,3QB-HU*#&%(X%"PQ(%"HH"<K@=*-0U)****8S__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  _ % # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@"GJ
MM_;:;ID]U=\P(OS+C.[/ 7TY)QSQS4$%C++ LLDLMK,QW;(6P$!P=N.0>G)_
M(XI==TD:SICVPE>&4'?%(KNNUQT)VL"1STS4%M=ZU;1,NH64$HCX^T13A1(
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MTN%O(3[=+-)$J$?*-C,"3SZ+T!ZFB[O<+*UCBKPV]WI$UBVIZK,KQ%/L*>'
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>>(I-/GME#0[)85DP48LQ)Q@<@ ?6J4GV)<5W/__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
